Related Experiment Video

Updated: Sep 20, 2026

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

Thalidomide down-regulates the expression of VEGF and bFGF in cisplatin-resistant human lung carcinoma cells

Xiping Li1, Xuyi Liu, Jie Wang

  • 1Mary Babb Randolph Cancer Center, Department of Microbiology, Immunology and Cell Biology, West Virginia University Robert C. Byrd Health Sciences Center, Morgantown, WV 26506, USA.

Anticancer Research
|August 5, 2003
PubMed

Insights

Thalidomide effectively suppresses vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in cisplatin-resistant lung cancer cells. This finding supports thalidomide

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Anti-angiogenic therapy is a key strategy in cancer treatment.
  • Thalidomide is known to inhibit angiogenesis and overcome drug resistance.
  • Its effect on angiogenic factors in cisplatin-resistant tumors remains unclear.

Purpose of the Study:

  • To investigate the impact of thalidomide on angiogenic growth factor expression in cisplatin-resistant lung cancer cells.
  • To evaluate thalidomide's potential in overcoming cisplatin resistance in lung carcinoma.

Main Methods:

  • Treatment of cisplatin-resistant human A549DDP lung carcinoma cells with thalidomide.
  • Analysis of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) mRNA levels using RT-PCR.
  • Quantification of VEGF and bFGF protein levels via dose- and time-dependent assays.

Main Results:

  • Thalidomide significantly decreased both mRNA and protein levels of VEGF and bFGF in A549DDP cells.
  • Suppression of growth factors occurred in a dose- and time-dependent manner.
  • Therapeutic concentrations of thalidomide (0.6-6 µg/ml) were effective.

Conclusions:

  • Thalidomide demonstrates potent suppression of key angiogenic factors in cisplatin-resistant lung cancer.
  • These findings suggest thalidomide's therapeutic potential for cisplatin-resistant lung cancer.
  • Further research into thalidomide's application in other resistant tumors is warranted.

More Related Videos

A Murine Cell Line Based Model of Chronic CDK9 Inhibition to Study Widespread Non-Genetic Transcriptional Elongation Defects (TEdeff) in Cancers10:49

A Murine Cell Line Based Model of Chronic CDK9 Inhibition to Study Widespread Non-Genetic Transcriptional Elongation Defects (TEdeff) in Cancers

Published on: September 26, 2019

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...